Cardiotoxicity in Adjuvant and Neoadjuvant Therapy for Breast Cancer

Detalhes bibliográficos
Autor(a) principal: Pina, Livia Christina de Oliveira
Data de Publicação: 2019
Outros Autores: Axelband, Flavia, Barbosa, Maria Fernanda, Silva, Mario Jorge Sobreira da
Tipo de documento: Artigo
Idioma: por
eng
Título da fonte: Revista Brasileira de Cancerologia (Online)
Texto Completo: https://rbc.inca.gov.br/index.php/revista/article/view/404
Resumo: Introduction: Breast cancer is the most common among women worldwide, accounting for almost 25% of all cancer cases. Some drugs have a peculiar characteristic related to cardiotoxicity. Objective: Analyze the incidence, clinical characteristics and risk factors associated with cardiotoxicity in patients undergoing protocol doxorubicin and cyclophosphamide followed or not by taxanes and in those who underwent the same protocol associated with trastuzumab. Method: Cohort study conducted in a public hospital in Rio de Janeiro. 153 patients were included between September and November 2012. Cardiotoxicity was defined based on the criteria of the Cardiac Review and Evaluation Committee and the Brazilian Society of Cardiology. The relative risk (RR) was calculated using a 95% confidence interval (CI). Results: The incidence of cardiotoxicity was 17%. Left ventricular ejection fraction decreased in 31.3% and 52.2% of the patients in the negative and positive human epidermal growth factor receptor-type 2 (HER-2) groups, respectively. Three cases of heart failure were identified, two in HER-2 positive patients. Patients using trastuzumab had a higher risk of developing cardiotoxicity (RR=3.53; CI 95%: 1.84-6.79) compared to women in the HER-2 negative group. Conclusion: It was possible to verify the occurrence of cases of cardiotoxicity in both groups with higher incidence for the HER-2 positive group.
id INCA-1_bdb829092f243df43018817fe70924ba
oai_identifier_str oai:rbc.inca.gov.br:article/404
network_acronym_str INCA-1
network_name_str Revista Brasileira de Cancerologia (Online)
repository_id_str
spelling Cardiotoxicity in Adjuvant and Neoadjuvant Therapy for Breast CancerCardiotoxicidad en Terapias de Cáncer de Mama Neoadyuvante y AdyuvanteCardiotoxicidade nas Terapias Neoadjuvante e Adjuvante do Câncer de MamaCardiotoxicidadeNeoplasias da MamaDoxorrubicinaCiclofosfamidaTrastuzumabCardiotoxicityBreast NeoplasmsDoxorubicinCyclophosphamideTrastuzumabCardiotoxicidadNeoplasias de la MamaDoxorrubicinaCiclofosfamidaTrastuzumabIntroduction: Breast cancer is the most common among women worldwide, accounting for almost 25% of all cancer cases. Some drugs have a peculiar characteristic related to cardiotoxicity. Objective: Analyze the incidence, clinical characteristics and risk factors associated with cardiotoxicity in patients undergoing protocol doxorubicin and cyclophosphamide followed or not by taxanes and in those who underwent the same protocol associated with trastuzumab. Method: Cohort study conducted in a public hospital in Rio de Janeiro. 153 patients were included between September and November 2012. Cardiotoxicity was defined based on the criteria of the Cardiac Review and Evaluation Committee and the Brazilian Society of Cardiology. The relative risk (RR) was calculated using a 95% confidence interval (CI). Results: The incidence of cardiotoxicity was 17%. Left ventricular ejection fraction decreased in 31.3% and 52.2% of the patients in the negative and positive human epidermal growth factor receptor-type 2 (HER-2) groups, respectively. Three cases of heart failure were identified, two in HER-2 positive patients. Patients using trastuzumab had a higher risk of developing cardiotoxicity (RR=3.53; CI 95%: 1.84-6.79) compared to women in the HER-2 negative group. Conclusion: It was possible to verify the occurrence of cases of cardiotoxicity in both groups with higher incidence for the HER-2 positive group.Introducción: El cáncer de mama es el más común entre las mujeres en todo el mundo, y representa casi el 25% de todos los casos de cáncer. Algunos medicamentos tienen característica peculiar relacionada con la cardiotoxicidad. Objetivo: Analizar la incidencia, las características clínicas y los factores de riesgo asociados con la cardiotoxicidad en pacientes sometidos al protocolo doxorrubicina y ciclofosfamida seguidos o no por taxanos y en aquellos que se sometieron al mismo protocolo asociado con trastuzumab. Método: Este es un estudio de cohorte realizado en un hospital público en Río de Janeiro. Se incluyeron 153 pacientes que comenzaron el tratamiento entre septiembre y noviembre de 2012. La cardiotoxicidad se definió según los criterios del Comité de Revisión y Evaluación Cardíaca y la Sociedad Brasileña de Cardiología. El riesgo relativo (RR) se calculó utilizando un intervalo de confianza (IC) del 95%. Resultados: La incidencia de cardiotoxicidad fue del 17%. La fracción de eyección del ventrículo izquierdo disminuyó en el 31,3% y el 52,2% de los pacientes en los grupos human epidermal growth factor receptor-type 2 (HER-2) negativo y positivo, respectivamente. Se identificaron tres casos de insuficiencia cardíaca, dos en pacientes con HER-2 positivo. Los pacientes que usaban trastuzumab tenían un mayor riesgo de desarrollar cardiotoxicidad (RR=3,53; IC 95%: 1,84-6,79) en comparación con las mujeres en el grupo negativo HER-2. Conclusión: Fue posible verificar la aparición de casos de cardiotoxicidad en ambos grupos con mayor incidencia para el grupo HER-2 positivo.Introdução: O câncer de mama é o mais comum entre as mulheres em todo o mundo, representando quase 25% de todos os casos de câncer. Alguns fármacos possuem características peculiares relacionadas à cardiotoxicidade. Objetivo: Analisar a incidência, as características clínicas e os fatores de risco associados à ocorrência de cardiotoxicidade em pacientes submetidas ao protocolo doxorrubicina e ciclofosfamida seguido ou não de taxanos e naquelas que realizaram o mesmo protocolo associado ao trastuzumabe. Método: Trata-se de um estudo de coorte realizado em um hospital público do Rio de Janeiro. Foram incluídas 153 pacientes que iniciaram tratamento entre os meses de setembro e novembro de 2012. A cardiotoxicidade foi definida com base nos critérios do Cardiac Review and Evaluation Committee e da Sociedade Brasileira de Cardiologia. Foi calculado o risco relativo (RR), utilizando-se um intervalo de confiança (IC) de 95%. Resultados: A incidência de cardiotoxicidade foi de 17%. Observou-se queda da fração de ejeção do ventrículo esquerdo em 31,3% e 52,2% das pacientes nos grupos human epidermal growth factor receptor-type 2 (HER-2) negativo e positivo, respectivamente. Foram identificados três casos de insuficiência cardíaca, sendo dois em pacientes HER-2 positivas. As pacientes que utilizaram trastuzumabe apresentaram maior risco de desenvolver cardiotoxicidade (RR=3,53; IC 95%: 1,84-6,79) em comparação com as mulheres do grupo HER-2 negativo. Conclusão: Foi possível verificar a ocorrência de casos de cardiotoxicidade em ambos os grupos com maior incidência para o grupo HER-2 positivo.INCA2019-11-26info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionArtigos, Avaliado pelos paresapplication/pdfapplication/pdfhttps://rbc.inca.gov.br/index.php/revista/article/view/40410.32635/2176-9745.RBC.2019v65n3.404Revista Brasileira de Cancerologia; Vol. 65 No. 3 (2019): July/Aug./Sept.; e-08404Revista Brasileira de Cancerologia; Vol. 65 Núm. 3 (2019): jul./agosto/sept.; e-08404Revista Brasileira de Cancerologia; v. 65 n. 3 (2019): jul./ago./set.; e-084042176-9745reponame:Revista Brasileira de Cancerologia (Online)instname:Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)instacron:INCAporenghttps://rbc.inca.gov.br/index.php/revista/article/view/404/490https://rbc.inca.gov.br/index.php/revista/article/view/404/609Copyright (c) 2019 Revista Brasileira de Cancerologiainfo:eu-repo/semantics/openAccessPina, Livia Christina de OliveiraAxelband, FlaviaBarbosa, Maria FernandaSilva, Mario Jorge Sobreira da2021-11-29T20:03:36Zoai:rbc.inca.gov.br:article/404Revistahttps://rbc.inca.gov.br/index.php/revistaPUBhttps://rbc.inca.gov.br/index.php/revista/oairbc@inca.gov.br0034-71162176-9745opendoar:2021-11-29T20:03:36Revista Brasileira de Cancerologia (Online) - Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)false
dc.title.none.fl_str_mv Cardiotoxicity in Adjuvant and Neoadjuvant Therapy for Breast Cancer
Cardiotoxicidad en Terapias de Cáncer de Mama Neoadyuvante y Adyuvante
Cardiotoxicidade nas Terapias Neoadjuvante e Adjuvante do Câncer de Mama
title Cardiotoxicity in Adjuvant and Neoadjuvant Therapy for Breast Cancer
spellingShingle Cardiotoxicity in Adjuvant and Neoadjuvant Therapy for Breast Cancer
Pina, Livia Christina de Oliveira
Cardiotoxicidade
Neoplasias da Mama
Doxorrubicina
Ciclofosfamida
Trastuzumab
Cardiotoxicity
Breast Neoplasms
Doxorubicin
Cyclophosphamide
Trastuzumab
Cardiotoxicidad
Neoplasias de la Mama
Doxorrubicina
Ciclofosfamida
Trastuzumab
title_short Cardiotoxicity in Adjuvant and Neoadjuvant Therapy for Breast Cancer
title_full Cardiotoxicity in Adjuvant and Neoadjuvant Therapy for Breast Cancer
title_fullStr Cardiotoxicity in Adjuvant and Neoadjuvant Therapy for Breast Cancer
title_full_unstemmed Cardiotoxicity in Adjuvant and Neoadjuvant Therapy for Breast Cancer
title_sort Cardiotoxicity in Adjuvant and Neoadjuvant Therapy for Breast Cancer
author Pina, Livia Christina de Oliveira
author_facet Pina, Livia Christina de Oliveira
Axelband, Flavia
Barbosa, Maria Fernanda
Silva, Mario Jorge Sobreira da
author_role author
author2 Axelband, Flavia
Barbosa, Maria Fernanda
Silva, Mario Jorge Sobreira da
author2_role author
author
author
dc.contributor.author.fl_str_mv Pina, Livia Christina de Oliveira
Axelband, Flavia
Barbosa, Maria Fernanda
Silva, Mario Jorge Sobreira da
dc.subject.por.fl_str_mv Cardiotoxicidade
Neoplasias da Mama
Doxorrubicina
Ciclofosfamida
Trastuzumab
Cardiotoxicity
Breast Neoplasms
Doxorubicin
Cyclophosphamide
Trastuzumab
Cardiotoxicidad
Neoplasias de la Mama
Doxorrubicina
Ciclofosfamida
Trastuzumab
topic Cardiotoxicidade
Neoplasias da Mama
Doxorrubicina
Ciclofosfamida
Trastuzumab
Cardiotoxicity
Breast Neoplasms
Doxorubicin
Cyclophosphamide
Trastuzumab
Cardiotoxicidad
Neoplasias de la Mama
Doxorrubicina
Ciclofosfamida
Trastuzumab
description Introduction: Breast cancer is the most common among women worldwide, accounting for almost 25% of all cancer cases. Some drugs have a peculiar characteristic related to cardiotoxicity. Objective: Analyze the incidence, clinical characteristics and risk factors associated with cardiotoxicity in patients undergoing protocol doxorubicin and cyclophosphamide followed or not by taxanes and in those who underwent the same protocol associated with trastuzumab. Method: Cohort study conducted in a public hospital in Rio de Janeiro. 153 patients were included between September and November 2012. Cardiotoxicity was defined based on the criteria of the Cardiac Review and Evaluation Committee and the Brazilian Society of Cardiology. The relative risk (RR) was calculated using a 95% confidence interval (CI). Results: The incidence of cardiotoxicity was 17%. Left ventricular ejection fraction decreased in 31.3% and 52.2% of the patients in the negative and positive human epidermal growth factor receptor-type 2 (HER-2) groups, respectively. Three cases of heart failure were identified, two in HER-2 positive patients. Patients using trastuzumab had a higher risk of developing cardiotoxicity (RR=3.53; CI 95%: 1.84-6.79) compared to women in the HER-2 negative group. Conclusion: It was possible to verify the occurrence of cases of cardiotoxicity in both groups with higher incidence for the HER-2 positive group.
publishDate 2019
dc.date.none.fl_str_mv 2019-11-26
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
Artigos, Avaliado pelos pares
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://rbc.inca.gov.br/index.php/revista/article/view/404
10.32635/2176-9745.RBC.2019v65n3.404
url https://rbc.inca.gov.br/index.php/revista/article/view/404
identifier_str_mv 10.32635/2176-9745.RBC.2019v65n3.404
dc.language.iso.fl_str_mv por
eng
language por
eng
dc.relation.none.fl_str_mv https://rbc.inca.gov.br/index.php/revista/article/view/404/490
https://rbc.inca.gov.br/index.php/revista/article/view/404/609
dc.rights.driver.fl_str_mv Copyright (c) 2019 Revista Brasileira de Cancerologia
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2019 Revista Brasileira de Cancerologia
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv INCA
publisher.none.fl_str_mv INCA
dc.source.none.fl_str_mv Revista Brasileira de Cancerologia; Vol. 65 No. 3 (2019): July/Aug./Sept.; e-08404
Revista Brasileira de Cancerologia; Vol. 65 Núm. 3 (2019): jul./agosto/sept.; e-08404
Revista Brasileira de Cancerologia; v. 65 n. 3 (2019): jul./ago./set.; e-08404
2176-9745
reponame:Revista Brasileira de Cancerologia (Online)
instname:Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)
instacron:INCA
instname_str Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)
instacron_str INCA
institution INCA
reponame_str Revista Brasileira de Cancerologia (Online)
collection Revista Brasileira de Cancerologia (Online)
repository.name.fl_str_mv Revista Brasileira de Cancerologia (Online) - Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)
repository.mail.fl_str_mv rbc@inca.gov.br
_version_ 1797042243676143616

Registros relacionados